Novaferon in Non-hospitalized Adult Patients With Mild COVID-19 - Trial NCT05172037
Access comprehensive clinical trial information for NCT05172037 through Pure Global AI's free database. This Phase 3 trial is sponsored by Genova Inc. and is currently Recruiting. The study focuses on Covid19. Target enrollment is 222 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Genova Inc.
Timeline & Enrollment
Phase 3
Oct 28, 2021
Jun 01, 2022
Primary Outcome
Rate of severe conditions with Score 3 or more serious on a seven-point ordinal scale from the start date of investigational drug administration (Day 1) to Day 28.
Summary
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to
 Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult
 Patients with Mild COVID-19
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05172037
Non-Device Trial